Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:28 PM
Ignite Modification Date:
2025-12-24 @ 11:28 PM
NCT ID:
NCT01444456
Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric cancer
* Expected to receive at least 8 additional weeks of a given regimen of myelosuppressive chemotherapy after enrolment
* Starting treatment with either darbepoetin alfa (in Cohort 1 countries) or any ESA (in Cohort 2 countries) as per European Summary of Product Characteristics (SPC) for symptomatic anaemia.
Exclusion Criteria:
* Received any ESA treatment or Red Blood Cell (RBC) transfusion within 28 days prior to enrolment
* Known primary benign or malignant haematologic disorder which can cause anaemia
* Known hypersensitivity to ESAs
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01444456
Study Brief:
Protocol Section:
NCT01444456